Glutamate transporter EAAT2: A new target for the treatment of neurodegenerative diseases

Future Medicinal Chemistry

Volumn 4, Issue 13, 2012, Pages 1689-1700

  Lin, Chien Liang Glenn ^a   Kong, Qiongman ^a   Cuny, Gregory D ^b,c   Glicksman, Marcie A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; CEFTRIAXONE; CORTICOSTERONE; DIHYDROKAINIC ACID; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; FANAPANEL; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GYKI 5377; LDN 212320; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RETINOL; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DEPTH STIMULATION; DEGENERATIVE DISEASE; EPILEPSY; EXCITOTOXICITY; GENE TARGETING; HUMAN; MOTONEURON; NERVE CELL LESION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROKE; SUBSTANTIA NIGRA; TRANSCRIPTION INITIATION; TRANSLATION INITIATION; UPREGULATION;

ANIMALS; GENE EXPRESSION REGULATION; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES;

EID: 84865783553     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.122     Document Type: Review

References (102)

1. Danbolt NC. Glutamate uptake. Prog. Neurobiol. 65(1), 1-105 (2001).
2. Takeuchi H, Jin S, Wang J et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 281(30), 21362-21368 (2006).
3. Wetherington J, Serrano G, Dingledine R. Astrocytes in the epileptic brain. Neuron 58(2), 168-178 (2008).
4. Choi DW. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7(2), 369-379 (1987).
5. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem. Int. 48(5), 394-403 (2006).
6. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 50(7-8), 941-953 (2007).
7. Acharya MM, Hattiangady B, Shetty AK. Progress in neuroprotective strategies for preventing epilepsy. Prog. Neurobiol. 84(4), 363-404 (2008).
8. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762(11-12), 1068-1082 (2006).
9. Koutsilieri E, Riederer P. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat. Disord. 13(Suppl. 3), S329-S331 (2007).
10. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Biomed. Pharmacother. 62(4), 199-207 (2008).
11. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5(2), 160-170 (2006).
12. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr. Dis. Treat. 5, 237-247 (2009).
13. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 17(18), 1942-1199 (2010).
14. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochr. Data. Syst. Rev. 3, CD001447 (2012).
15. Storck T, Schulte S, Hofmann K, Stoffel W. Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc. Natl Acad. Sci. USA 89(22), 10955-10959 (1992).
16. Pines G, Danbolt NC, Bjoras M et al. Cloning and expression of a rat brain l-glutamate transporter. Nature 360(6403), 464-467 (1992).
17. Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360(6403), 467-471 (1992).
18. Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 375(6532), 599-603 (1995).
19. Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc. Natl Acad. Sci. USA 94(8), 4155-4160 (1997).
20. Rothstein JD, Martin L, Levey AI et al. Localization of neuronal and glial glutamate transporters. Neuron 13(3), 713-725 (1994).
21. Liang J, Takeuchi H, Doi Y et al. Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity. Brain Res. 1210, 11-19 (2008).
22. Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 15(3), 711-720 (1995).
23. Rothstein JD, Dykes-Hoberg M, Pardo CA et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16(3), 675-686 (1996).
24. Tanaka K, Watase K, Manabe T et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276(5319), 1699-1702 (1997).
25. Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30(4), 572-580 (1991).
26. Greenamyre JT, Penney JB, Young AB, D'Amato CJ, Hicks SP, Shoulson I. Alterations in l-glutamate binding in Alzheimer's and Huntington's diseases. Science 227(4693), 1496-1499 (1985).
27. Simpson MD, Royston MC, Deakin JF, Cross AJ, Mann DM, Slater P. Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains. Brain Res. 462(1), 76-82 (1988).
28. Chalmers DT, Dewar D, Graham DI, Brooks DN, McCulloch J. Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc. Natl Acad. Sci. USA 87(4), 1352-1356 (1990).
29. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40(5), 759-766 (1996).
30. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56(8), 901-911 (1997).
31. Jacob CP, Koutsilieri E, Bartl J et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J. Alzheimers Dis. 11(1), 97-116 (2007).
32. Lauderback CM, Hackett JM, Huang FF et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78(2), 413-416 (2001).
33. Butchbach ME, Tian G, Guo H, Lin CL. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J. Biol. Chem. 279(33), 34388-34396 (2004).
34. Tian G, Kong Q, Lai L, Ray-Chaudhury A, Lin CL. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease. J. Neurochem. 113(4), 978-989 (2010).
35. McBean GJ, Roberts PJ. Neurotoxicity of l-glutamate and dl-threo-3-hydroxyaspartate in the rat striatum. J. Neurochem. 44(1), 247-254 (1985).
36. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci. USA 90(14), 6591-6595 (1993).
37. Arias C, Arrieta I, Massieu L, Tapia R. Neuronal damage and MAP2 changes induced by the glutamate transport inhibitor dihydrokainate and by kainate in rat hippocampus in vivo. Exp. Brain Res. 116(3), 467-476 (1997).
38. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65(Suppl. 1), S3-S9 (2009).
39. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52(1), 39-59 (2006).
40. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38(1), 73-84 (1995).
41. Bruijn LI, Becher MW, Lee MK et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18(2), 327-338 (1997).
42. Bendotti C, Tortarolo M, Suchak SK et al. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J. Neurochem. 79(4), 737-746 (2001).
43. Howland DS, Liu J, She Y et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 99(3), 1604-1609 (2002).
44. Guo H, Lai L, Butchbach ME et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 12(19), 2519-2532 (2003).
45. Rothstein JD, Patel S, Regan MR et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433(7021), 73-77 (2005).
46. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62(1), 63-88 (2000).
47. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12(10), 366-375 (1989).
48. Bezard E, Boraud T, Bioulac B, Gross CE. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11(6), 2167-2170 (1999).
49. Klockgether T, Turski L, Honore T et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30(5), 717-723 (1991).
50. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35(6), 655-661 (1994).
51. Starr MS. Antiparkinsonian actions of glutamate antagonists-alone and with l-DOPA: a review of evidence and suggestions for possible mechanisms. J. Neural Transm. Park. Dis. Dement. Sect. 10(2-3), 141-185 (1995).
52. Battaglia G, Busceti CL, Pontarelli F et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45(2), 155-166 (2003).
53. Corti C, Battaglia G, Molinaro G et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 27(31), 8297-8308 (2007).
54. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41(4), 413-420 (2001).
55. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22(13), 5669-5678 (2002).
56. Battaglia G, Busceti CL, Molinaro G et al. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24(4), 828-835 (2004).
57. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249(4975), 1436-1438 (1990).
58. Limousin P, Krack P, Pollak P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339(16), 1105-1111 (1998).
59. Wallace BA, Ashkan K, Heise CE et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130(Pt 8), 2129-2145 (2007).
60. Chung EK, Chen LW, Chan YS, Yung KK. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine- lesioned rats. J. Comp. Neurol. 511(4), 421-437 (2008).
61. Holmer HK, Keyghobadi M, Moore C, Meshul CK. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 136(1), 333-341 (2005).
62. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42(6), 796-803 (2001).
63. McNamara JO, Huang YZ, Leonard AS. Molecular signaling mechanisms underlying epileptogenesis. Sci STKE 2006(356), re12 (2006).
64. Devinsky O. Diagnosis and treatment of temporal lobe epilepsy. Rev. Neurol. Dis. 1(1), 2-9 (2004).
65. Cavus I, Kasoff WS, Cassaday MP et al. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann. Neurol. 57(2), 226-235 (2005).
66. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341(8861), 1607-1610 (1993).
67. Tian GF, Azmi H, Takano T et al. An astrocytic basis of epilepsy. Nat. Med. 11(9), 973-981 (2005).
68. Binder DK, Steinhauser C. Functional changes in astroglial cells in epilepsy. Glia 54(5), 358-368 (2006).
69. Benarroch EE. Astrocyte-neuron interactions: implications for epilepsy. Neurology 73(16), 1323-1327 (2009).
70. Bjornsen LP, Eid T, Holmseth S, Danbolt NC, Spencer DD, de Lanerolle NC. Changes in glial glutamate transporters in human epileptogenic hippocampus: inadequate explanation for high extracellular glutamate during seizures. Neurobiol. Dis. 25(2), 319-330 (2007).
71. Sarac S, Afzal S, Broholm H, Madsen FF, Ploug T, Laursen H. Excitatory amino acid transporters EAAT-1 and EAAT-2 in temporal lobe and hippocampus in intractable temporal lobe epilepsy. APMIS 117(4), 291-301 (2009).
72. Kong Q, Takahashi K, Schulte D, Stouffer N, Lin Y, Lin CL. Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus. Neurobiol. Dis. 47(2), 145-154 (2012).
73. Compston A, Coles A. Multiple sclerosis. Lancet 372(9648), 1502-1517 (2008).
74. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128(Pt 5), 1016-1025 (2005).
75. Stover JF, Pleines UE, Morganti-Kossmann MC, Kossmann T, Lowitzsch K, Kempski OS. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest. 27(12), 1038-1043 (1997).
76. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 53(2), 212-224 (2006).
77. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6(1), 62-66 (2000).
78. Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. 137(2), 89-96 (1996).
79. Bolton C, Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J. Pharmacol. Exp. Ther. 282(1), 397-402 (1997).
80. Mitosek-Szewczyk K, Sulkowski G, Stelmasiak Z, Struzynska L. Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis. Neuroscience 155(1), 45-52 (2008).
81. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 55(3), 310-318 (2008).
82. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43(5), 1369-1374 (1984).
83. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 403(6767), 316-321 (2000).
84. Phillis JW, Ren J, O'Regan MH. Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with dl-threo-beta-benzyloxyaspartate. Brain Res. 868(1), 105-112 (2000).
85. Rao VL, Dogan A, Bowen KK, Todd KG, Dempsey RJ. Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain. Eur. J. Neurosci. 13(1), 119-128 (2001).
86. Weller ML, Stone IM, Goss A, Rau T, Rova C, Poulsen DJ. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia. Neuroscience 155(4), 1204-1211 (2008).
87. Chu K, Lee ST, Sinn DI et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 38(1), 177-182 (2007).
88. Harvey BK, Airavaara M, Hinzman J et al. Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS ONE 6(8), e22135 (2011).
89. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244(4906), 798-800 (1989).
90. Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD. Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J. Neurochem. 65(4), 1704-1711 (1995).
91. Bullock R, Zauner A, Woodward JJ et al. Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89(4), 507-518 (1998).
92. Koizumi H, Fujisawa H, Ito H, Maekawa T, Di X, Bullock R. Effects of mild hypothermia on cerebral blood flow-independent changes in cortical extracellular levels of amino acids following contusion trauma in the rat. Brain Res. 747(2), 304-312 (1997).
93. Yi JH, Hoover R, McIntosh TK, Hazell AS. Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine. J. Neurotrauma 23(1), 86-96 (2006).
94. Yi JH, Pow DV, Hazell AS. Early loss of the glutamate transporter splice-variant GLT-1v in rat cerebral cortex following lateral fluid-percussion injury. Glia 49(1), 121-133 (2005).
95. Zelenaia O, Schlag BD, Gochenauer GE et al. Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Mol. Pharmacol. 57(4), 667-678 (2000).
96. Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J. Regulation of glial glutamate transporter expression by growth factors. Exp. Neurol. 183(1), 124-135 (2003).
97. Tian G, Lai L, Guo H et al. Translational control of glial glutamate transporter EAAT2 expression. J. Biol. Chem. 282(3), 1727-1737 (2007).
98. Filosa A, Paixao S, Honsek SD et al. Neuron-glia communication via EphA4/ ephrin-A3 modulates LTP through glial glutamate transport. Nat. Neurosci. 12(10), 1285-1292 (2009).
99. Yang Y, Gozen O, Watkins A et al. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61(6), 880-894 (2009).
100. Su ZZ, Leszczyniecka M, Kang DC et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc. Natl Acad. Sci. USA 100(4), 1955-1960 (2003).
101. Colton CK, Kong Q, Lai L et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J. Biomol. Screen. 15(6), 653-662 (2010).
102. Xing X, Chang LC, Kong Q et al. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg. Med. Chem. Lett. 21(19), 5774-5777 (2011).